Intellectual property protection: Strategies for future antibody inventions

mAbs

Volumn 3, Issue 3, 2011, Pages 310-317

  Storz, Ulrich ^a  

^a NONE

Author keywords

Antibody; Intellectual property; Inventive; Mimetics; Patent

Indexed keywords

ADALIMUMAB; AFFILIN; ANTICALIN; BEVACIZUMAB; CETUXIMAB; CITALOPRAM; CYTOKINE; ESCITALOPRAM; ETANERCEPT; GOLIMUMAB; GT 468; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; MEMBRANE RECEPTOR; MM 111; MONOCLONAL ANTIBODY; MOTAVIZUMAB; NEUTROKINE ALPHA; OBINUTUZUMAB; OFATUMUMAB; OLANZAPINE; PALIVIZUMAB; RANIBIZUMAB; RITUXIMAB; SPHINGOMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY ENGINEERING; BINDING AFFINITY; BIOTECHNOLOGY; DECISION MAKING; DRUG CROSS REACTIVITY; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; NONHUMAN; PATENT; REVIEW; SOLID TUMOR;

ANTIBODIES; DRUG INDUSTRY; HUMANS; INTELLECTUAL PROPERTY; PATENTS AS TOPIC; TECHNOLOGY, PHARMACEUTICAL; TRANSLATIONAL MEDICAL RESEARCH;

EID: 79955667858     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.3.15530     Document Type: Review

References (22)

1. McCabe K. Guardians at the gate: Patent protection for therapeutic monoclonal antibodies-part 1. mAbs 2009; 1:382-4.
2. www.epo.org/law-practice/case-law-appeals/search.html
3. EPO Technical Board decision T0601/05, 2009. EPO Board of appeal decisions database T0601/05.
4. Köhler GF, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7.
5. EPO Technical Board decision T0018/09, 2009, EPO Board of appeal decisions database T0018/09.
6. Eli Lilly and Company vs. Human Genome Sciences, [2008] EWHC 1903 (Pat), 2008 Bailii EWHC 1903.
7. Centocor Ortho Biotech, Inc., v. Abbott Labs, 07-CV-0139, 2011 US App. LEXIS 3514.
8. Ariad Pharmaceuticals, Inc., v. Eli Lilly and Company, 598 F.3d 1336, 2010 US App. LEXIS 5966.
9. Generics UK vs. Daiichi, [2008] EWHC 2413 (Pat), 2008 Bailii EWHC 2413.
10. Escitalopram, Xa ZR 130/07 (BPatG), 2009, GRUR 2010; 123.
11. Forest Labs., Inc., v. Ivax Pharm., Inc., 501 F.3d 1263, 2007 US App. LEXIS 21165.
12. Dr. Reddy's vs. Eli Lilly and Company, [2008] EWHC 2345 (Pat), 2008 Bailii EWHC 2345.
13. Olanzapin X ZR 89/07 (BPatG) 2008, GRUR 2009; 382.
14. Eli Lilly & Co., v. Zenith Goldline Pharm., Inc., 05-1396, 05-1429, 05-1430, 2007 US App. LEXIS 8750.
15. nd edition. Springer 2010; 517-81.
16. Guideline on similar biological medicinal products containing monoclonal antibodies (EMA/CHMP/BMWP/403543/2010), and Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use (EMA/CHMP/BMWP/86289/2010). www.ema.europa.eu
17. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985-90.
18. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006; 5:993-6.
19. Noelle v. Lederman, 355 F.3d 1343, 2004 US App. LEXIS 774.
20. EPO Technical Board decision T0542/95, 1999, EPO Board of appeal decisions database T0542/95.
21. +) cancers. J Clin Oncol (Meeting Abstracts) May 2010; 28:15.
22. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13:245-55.